Drug Name: Relyvrio
Active Ingredient: sodium phenylbutyrate/taurursodiol
Indications: To treat amyotrophic lateral sclerosis (ALS)
Approval Date: 9/29/2022
Company: Amylyx Pharmaceuticals, Inc
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216660s000lbledt.pdf